Genmab A/S (NASDAQ:GMAB) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS

Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings data on Wednesday. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29, Zacks reports. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. Genmab A/S updated its FY 2025 guidance to EPS.

Genmab A/S Price Performance

GMAB stock traded up $0.50 during mid-day trading on Wednesday, reaching $19.39. The company had a trading volume of 1,154,362 shares, compared to its average volume of 1,523,209. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.88. The company has a market capitalization of $12.83 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 0.54 and a beta of 0.96. The stock has a 50 day simple moving average of $20.72 and a two-hundred day simple moving average of $23.24.

Analysts Set New Price Targets

Several equities research analysts have recently commented on GMAB shares. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.